Adage Capital Partners Gp, L.L.C. Cardiff Oncology, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $51.6 Billion
- Q1 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 1,445,000 shares of CRDF stock, worth $3.73 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,445,000
Previous 1,292,308
11.82%
Holding current value
$3.73 Million
Previous $5.61 Million
19.1%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding CRDF
# of Institutions
124Shares Held
29.4MCall Options Held
900KPut Options Held
234K-
Commodore Capital LP New York, NY5.38MShares$13.9 Million1.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.12MShares$8.04 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$6.78 Million0.0% of portfolio
-
Blair William & CO Chicago, IL2.52MShares$6.51 Million0.02% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.44MShares$3.72 Million3.15% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $112M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...